Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:William_Collier
|
| gptkbp:collaboratesWith |
gptkb:Alnylam_Pharmaceuticals
gptkb:Genevant_Sciences |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
RNA interference therapeutics
hepatitis B virus therapeutics |
| gptkbp:formerName |
gptkb:Tekmira_Pharmaceuticals
|
| gptkbp:foundedYear |
2007
|
| gptkbp:headquartersLocation |
gptkb:Warminster,_Pennsylvania,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Arbutus Biopharma
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:legalForm |
gptkb:public_company
|
| gptkbp:notableProduct |
gptkb:AB-101
gptkb:AB-729 gptkb:AB-836 |
| gptkbp:numberOfEmployees |
~100 (as of 2023)
|
| gptkbp:parentCompany |
nan
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:researchArea |
antiviral therapeutics
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:ABUS
|
| gptkbp:website |
https://www.arbutusbio.com/
|
| gptkbp:bfsParent |
gptkb:Genevant_Sciences
|
| gptkbp:bfsLayer |
6
|